CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Pilot Randomized Controlled Trial of an Educational Video for CAR T-Cell Therapy Recipients.
Pilot Randomized Controlled Trial of an Educational Video for CAR T-Cell Therapy Recipients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们发现,面向接受 CAR T-cell 治疗患者的教育视频是可行且可接受的。该教育视频在患者自我效能和决策满意度方面显示出有前景的初步效果,值得进一步研究。
CAR-T 细胞疗法已经改变了血液系统恶性肿瘤的治疗格局,但其机制复杂,向患者传达时具有挑战性。教育性视频干预在提高患者对肿瘤治疗方案的认知、帮助其明确治疗偏好方面已被证实有效,然而目前尚无针对CAR-T 细胞疗法的教育性视频经过评估。
我们在麻省总医院开展了一项随机对照试验,在患有血液系统恶性肿瘤且正在接受 CAR-T 细胞治疗的成人(年龄 18 岁)中,比较教育视频与常规护理。干预组参与者观看了一段 13 分钟的视频,内容描述了 CAR-T 细胞治疗如何发挥作用、流程、毒性、预后、康复以及应对预后不确定性的方法。主要结局为可行性(60% 入组率)。次要结局包括可接受性(80% 报告对视频感到舒适)、患者对 CAR-T 细胞治疗的知识(10 项测试)、自我效能(沟通与态度自我效能量表-癌症)、决策满意度(决策冲突量表)、心理痛苦(医院焦虑抑郁量表)以及对 CAR-T 细胞治疗的偏好。
我们纳入了79%(80/101)的合格患者。在该组中,91%(30/33)报告观看视频时非常或有些舒适,94%(31/33)肯定会或可能会推荐该视频。在1个月时,视频组参与者报告了更高的自我效能(平均差异[MD],9.2 [95% CI,-4.0至22.3];Cohen's d,0.32)、决策满意度(MD,2.5 [95% CI,0.7-4.2];Cohen's d,0.67)和更低的焦虑(MD,-0.8 [95% CI,-2.5至0.7];Cohen's d,0.26),与常规护理组参与者相比。在1周时,两组均报告了对CAR-T 细胞疗法的高偏好(视频组,94% [33/35];常规护理组,84% [27/32])。
CAR T-cell therapy has transformed the treatment of hematologic malignancies, but it is complex and challenging to convey to patients. Educational video interventions are efficacious for improving patient knowledge about cancer therapeutics and informing their care preferences, yet no educational videos have been evaluated in CAR T-cell therapy.
We conducted a randomized controlled trial comparing an educational video versus usual care in adults (age 18 years) with hematologic malignancies receiving CAR T-cell therapy at Massachusetts General Hospital. Intervention participants watched a 13-minute video depicting how CAR T-cell therapy works, logistics, toxicities, prognosis, recovery, and approaches for dealing with prognostic uncertainty. The primary outcome was feasibility ( 60% enrollment rate). Secondary outcomes included acceptability ( 80% reporting comfort with the video), patients' knowledge about CAR T-cell therapy (10-item test), and self-efficacy (Communication and Attitudinal Self-Efficacy Scale-Cancer), decision satisfaction (Decision Conflict Scale), psychological distress (Hospital Anxiety and Depression Scale), and preference for CAR T-cell therapy.
We enrolled 79% (80/101) of eligible patients. Of that group, 91% (30/33) reported being very or somewhat comfortable watching the video, and 94% (31/33) would definitely or probably recommend the video. At 1 month, participants in the video arm reported higher self-efficacy (mean difference [MD], 9.2 [95% CI, -4.0 to 22.3]; Cohen's d, 0.32), decision satisfaction (MD, 2.5 [95% CI, 0.7-4.2]; Cohen's d, 0.67), and lower anxiety (MD, -0.8 [95% CI, -2.5 to 0.7]; Cohen's d, 0.26) compared with participants in the usual care arm. At 1 week, both arms reported high preferences for CAR T-cell therapy (video arm, 94% [33/35]; usual care, 84% [27/32]).
We found that an educational video for patients receiving CAR T-cell therapy was feasible and acceptable. The educational video demonstrated promising preliminary effects on patient self-efficacy and decision satisfaction and warrants further study.
MEMBER ACCOUNT
登录成功会直接打开下一页。